• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

2120 例胶质瘤患者中 C1RL 的免疫组化和临床病理特征。

Immunological and clinicopathological characteristics of C1RL in 2120 glioma patients.

机构信息

Department of Neurosurgery, The First People's Hospital of Wenling, Wenling, 317500, China.

Department of Neurosurgery, Tianjin Medical University General Hospital, Tianjin, 300052, China.

出版信息

BMC Cancer. 2020 Sep 29;20(1):931. doi: 10.1186/s12885-020-07436-6.

DOI:10.1186/s12885-020-07436-6
PMID:32993564
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7526369/
Abstract

BACKGROUND

Glioma is a deadly and immunosuppressive brain tumour. Complement C1r subcomponent like (C1RL), a prognostic biomarker in several kinds of tumours, has attracted increasing attention from oncologists. However, the role of C1RL in glioma remains unclear.

METHODS

Through analysis of 2120 glioma patients from 5 public datasets, the relationships between C1RL expression and clinicopathological characteristics were evaluated. Furthermore, the C1RL-associated genes were screened, and Gene Ontology (GO) analysis was conducted to investigate biological process enrichment. In addition, tumour purity, leukocyte infiltration and overall survival were evaluated based on C1RL expression.

RESULTS

We found that C1RL expression was upregulated in glioblastoma (GBM), especially mesenchymal GBM and primary GBM. Increased C1RL expression accompanied the IDH1-wt phenotype in both lower grade glioma (LGG) and GBM. C1RL- associated genes were mainly enriched in biological processes related to the immune response. C1RL expression was also correlated with reduced tumour purity and increased M2 macrophage infiltration. Higher C1RL expression predicted unfavourable survival in patients with glioma and therapeutic resistance in GBM.

CONCLUSIONS

Our results imply that C1RL is involved in immunological activities and is an independent unfavourable prognostic biomarker in patients with glioma. C1RL is a potential clinical immunotherapeutic target for glioma treatment in the future.

摘要

背景

神经胶质瘤是一种致命且免疫抑制的脑肿瘤。补体 C1r 亚基样（C1RL）是几种肿瘤的预后生物标志物，已引起肿瘤学家的越来越多关注。然而，C1RL 在神经胶质瘤中的作用仍不清楚。

方法

通过对 5 个公共数据集的 2120 名神经胶质瘤患者进行分析，评估了 C1RL 表达与临床病理特征之间的关系。此外，筛选了与 C1RL 相关的基因，并进行了基因本体论（GO）分析，以研究生物学过程的富集。此外，还根据 C1RL 表达评估了肿瘤纯度、白细胞浸润和总生存期。

结果

我们发现 C1RL 在胶质母细胞瘤（GBM）中表达上调，尤其是间充质 GBM 和原发性 GBM。在低级别神经胶质瘤（LGG）和 GBM 中，IDH1-wt 表型伴随 C1RL 表达增加。C1RL 相关基因主要富集在与免疫反应相关的生物学过程中。C1RL 表达还与肿瘤纯度降低和 M2 巨噬细胞浸润增加有关。C1RL 高表达预示着神经胶质瘤患者的生存预后不良和 GBM 治疗耐药。

结论

我们的研究结果表明，C1RL 参与免疫活性，是神经胶质瘤患者独立的不良预后生物标志物。C1RL 可能成为未来神经胶质瘤治疗的潜在临床免疫治疗靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3fa5/7526369/69d73d690a02/12885_2020_7436_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3fa5/7526369/30d7166bda12/12885_2020_7436_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3fa5/7526369/ca1905e6ddf3/12885_2020_7436_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3fa5/7526369/d2a6b015fc1a/12885_2020_7436_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3fa5/7526369/0040d876f936/12885_2020_7436_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3fa5/7526369/69d73d690a02/12885_2020_7436_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3fa5/7526369/30d7166bda12/12885_2020_7436_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3fa5/7526369/ca1905e6ddf3/12885_2020_7436_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3fa5/7526369/d2a6b015fc1a/12885_2020_7436_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3fa5/7526369/0040d876f936/12885_2020_7436_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3fa5/7526369/69d73d690a02/12885_2020_7436_Fig5_HTML.jpg

相似文献

1
Immunological and clinicopathological characteristics of C1RL in 2120 glioma patients.2120 例胶质瘤患者中 C1RL 的免疫组化和临床病理特征。
BMC Cancer. 2020 Sep 29;20(1):931. doi: 10.1186/s12885-020-07436-6.
2
Identification of potential biomarkers related to glioma survival by gene expression profile analysis.通过基因表达谱分析鉴定与胶质瘤生存相关的潜在生物标志物。
BMC Med Genomics. 2019 Mar 20;11(Suppl 7):34. doi: 10.1186/s12920-019-0479-6.
3
SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA data.SYT16 是胶质母细胞瘤的预后生物标志物，并与免疫浸润相关：基于 TCGA 数据的研究。
Int Immunopharmacol. 2020 Jul;84:106490. doi: 10.1016/j.intimp.2020.106490. Epub 2020 Apr 11.
4
ARL3 is downregulated and acts as a prognostic biomarker in glioma.ARL3 在神经胶质瘤中下调并作为预后生物标志物。
J Transl Med. 2019 Jun 24;17(1):210. doi: 10.1186/s12967-019-1914-3.
5
Immune heterogeneity and clinicopathologic characterization of IGFBP2 in 2447 glioma samples.2447例胶质瘤样本中IGFBP2的免疫异质性及临床病理特征
Oncoimmunology. 2018 Feb 13;7(5):e1426516. doi: 10.1080/2162402X.2018.1426516. eCollection 2018.
6
Identification of a five B cell-associated gene prognostic and predictive signature for advanced glioma patients harboring immunosuppressive subtype preference.鉴定一种与五个B细胞相关基因的预后和预测特征，用于具有免疫抑制亚型偏好的晚期胶质瘤患者。
Oncotarget. 2016 Nov 8;7(45):73971-73983. doi: 10.18632/oncotarget.12605.
7
CLEC5A expressed on myeloid cells as a M2 biomarker relates to immunosuppression and decreased survival in patients with glioma.CLEC5A 在髓系细胞上的表达作为 M2 标志物与胶质瘤患者的免疫抑制和生存率降低有关。
Cancer Gene Ther. 2020 Sep;27(9):669-679. doi: 10.1038/s41417-019-0140-8. Epub 2019 Oct 8.
8
Gene Expression Profiling Stratifies IDH1-Mutant Glioma with Distinct Prognoses.基因表达谱分析将 IDH1 突变型胶质瘤分为具有不同预后的亚型。
Mol Neurobiol. 2017 Oct;54(8):5996-6005. doi: 10.1007/s12035-016-0150-6. Epub 2016 Sep 30.
9
Integrative analysis of KIF4A, 9, 18A, and 23 and their clinical significance in low-grade glioma and glioblastoma.KIF4A、9、18A 和 23 的综合分析及其在低级别胶质瘤和胶质母细胞瘤中的临床意义。
Sci Rep. 2019 Mar 14;9(1):4599. doi: 10.1038/s41598-018-37622-3.
10
CKMT1B is a potential prognostic biomarker and associated with immune infiltration in Lower-grade glioma.CKMT1B 是低级别神经胶质瘤的一个潜在预后生物标志物，并与免疫浸润相关。
PLoS One. 2021 Jan 19;16(1):e0245524. doi: 10.1371/journal.pone.0245524. eCollection 2021.

引用本文的文献

1
Modeling integration site data for safety assessment with MELISSA.使用MELISSA对整合位点数据进行安全性评估建模。
Nat Commun. 2025 Aug 23;16(1):7868. doi: 10.1038/s41467-025-63017-w.
2
An anoikis-related gene signature predicts prognosis, drug sensitivity, and immune microenvironment in cholangiocarcinoma.一种与失巢凋亡相关的基因特征可预测胆管癌的预后、药物敏感性和免疫微环境。
Heliyon. 2024 Jun 3;10(11):e32337. doi: 10.1016/j.heliyon.2024.e32337. eCollection 2024 Jun 15.
3
Complement and coagulation cascades are associated with prognosis and the immune microenvironment of lower-grade glioma.

本文引用的文献

1
MicroRNA-21 and microRNA-155 promote the progression of Burkitt's lymphoma by the PI3K/AKT signaling pathway.微小RNA-21和微小RNA-155通过PI3K/AKT信号通路促进伯基特淋巴瘤的进展。
Int J Clin Exp Pathol. 2020 Jan 1;13(1):89-98. eCollection 2020.
2
Elevated lymphocyte specific protein 1 expression is involved in the regulation of leukocyte migration and immunosuppressive microenvironment in glioblastoma.淋巴细胞特异性蛋白 1 表达水平升高参与胶质母细胞瘤中白细胞迁移和免疫抑制微环境的调节。
Aging (Albany NY). 2020 Jan 29;12(2):1656-1684. doi: 10.18632/aging.102706.
3
Prognostic Implications of the Complement Protein C1q in Gliomas.
补体和凝血级联反应与低级别胶质瘤的预后及免疫微环境相关。
Transl Cancer Res. 2024 Jan 31;13(1):112-136. doi: 10.21037/tcr-23-906. Epub 2024 Jan 29.
4
The genes significantly associated with an improved prognosis and long-term survival of glioblastoma.与胶质母细胞瘤预后改善和长期生存显著相关的基因。
PLoS One. 2023 Nov 29;18(11):e0295061. doi: 10.1371/journal.pone.0295061. eCollection 2023.
5
LC-MS/MS Quantitation of HILIC-Enriched -glycopeptides Derived from Low-Abundance Serum Glycoproteins in Patients with Narcolepsy Type 1.LC-MS/MS 定量分析 1 型发作性睡病患者低丰度血清糖蛋白衍生的 HILIC 富集-β-糖肽
Biomolecules. 2023 Oct 28;13(11):1589. doi: 10.3390/biom13111589.
6
LC-MS/MS-Based Proteomics Approach for the Identification of Candidate Serum Biomarkers in Patients with Narcolepsy Type 1.基于 LC-MS/MS 的蛋白质组学方法鉴定 1 型发作性睡病患者的候选血清生物标志物。
Biomolecules. 2023 Feb 23;13(3):420. doi: 10.3390/biom13030420.
7
The immune regulation of BCL3 in glioblastoma with mutated IDH1.IDH1 突变型胶质母细胞瘤中 BCL3 的免疫调控。
Aging (Albany NY). 2022 Apr 29;14(9):3856-3873. doi: 10.18632/aging.204048.
补体蛋白 C1q 在神经胶质瘤中的预后意义。
Front Immunol. 2019 Oct 10;10:2366. doi: 10.3389/fimmu.2019.02366. eCollection 2019.
4
Molecular and clinical characterization of Galectin-9 in glioma through 1,027 samples.通过 1027 个样本对神经胶质瘤中半乳糖凝集素-9 的分子和临床特征进行分析。
J Cell Physiol. 2020 May;235(5):4326-4334. doi: 10.1002/jcp.29309. Epub 2019 Oct 14.
5
CLEC5A expressed on myeloid cells as a M2 biomarker relates to immunosuppression and decreased survival in patients with glioma.CLEC5A 在髓系细胞上的表达作为 M2 标志物与胶质瘤患者的免疫抑制和生存率降低有关。
Cancer Gene Ther. 2020 Sep;27(9):669-679. doi: 10.1038/s41417-019-0140-8. Epub 2019 Oct 8.
6
Mesenchymal Stem Cells Derived and Cultured from Glioblastoma Multiforme Increase Tregs, Downregulate Th17, and Induce the Tolerogenic Phenotype of Monocyte-Derived Cells.源自多形性胶质母细胞瘤并培养的间充质干细胞增加调节性T细胞、下调辅助性T细胞17，并诱导单核细胞衍生细胞的致耐受性表型。
Stem Cells Int. 2019 May 2;2019:6904638. doi: 10.1155/2019/6904638. eCollection 2019.
7
Prognostic genes of hepatocellular carcinoma based on gene coexpression network analysis.基于基因共表达网络分析的肝细胞癌预后基因
J Cell Biochem. 2019 Jul;120(7):11616-11623. doi: 10.1002/jcb.28441. Epub 2019 Feb 18.
8
Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor.继发性胶质母细胞瘤的突变特征指导脑肿瘤中针对 MET 的靶向试验。
Cell. 2018 Nov 29;175(6):1665-1678.e18. doi: 10.1016/j.cell.2018.09.038. Epub 2018 Oct 18.
9
Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors.在脑胶质瘤和其他颅内肿瘤的情况下，T 细胞在骨髓中的隔离。
Nat Med. 2018 Sep;24(9):1459-1468. doi: 10.1038/s41591-018-0135-2. Epub 2018 Aug 13.
10
Treatment recommendations for elderly patients with newly diagnosed glioblastoma lack worldwide consensus.对于新诊断出的胶质母细胞瘤老年患者，缺乏全球治疗推荐共识。
J Neurooncol. 2018 Nov;140(2):421-426. doi: 10.1007/s11060-018-2969-3. Epub 2018 Aug 7.